We are live on ! Find out more
SGM

Seven Grand Managers Portfolio holdings

AUM $1.5B
1-Year Est. Return 57.16%
This Fund
S&P 500
This Quarter Est. Return
+11.24%
1 Year Est. Return
+57.16%
3 Year Est. Return
+233.02%
5 Year Est. Return
10 Year Est. Return
AUM
$1.5B
AUM Growth
+$183M
Cap. Flow
+$155M
Cap. Flow %
10.34%
Top 10 Hldgs %
42.84%
Holding
214
New
76
Increased
20
Reduced
18
Closed
47

Sector Composition

1 Industrials 23.49%
2 Healthcare 18.53%
3 Technology 17.09%
4 Energy 11.6%
5 Consumer Discretionary 9.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HTO
151
H2O America
HTO
$2.74B
$880K 0.06%
+15,000
New +$816K
BIOA
152
BioAge Labs
BIOA
$1.01B
$875K 0.06%
+50,000
New +$963K
EIKN
153
Eikon Therapeutics
EIKN
$529M
$846K 0.06%
+80,000
New +$1.07M
BOW
154
Bowhead Specialty Holdings
BOW
$1.01B
$841K 0.06%
37,500
GLUE icon
155
Monte Rosa Therapeutics
GLUE
$2.07B
$740K 0.05%
+45,000
New +$861K
CRVS icon
156
Corvus Pharmaceuticals
CRVS
$1.25B
$732K 0.05%
+50,000
New +$798K
AGBK
157
AGI Inc
AGBK
$1.11B
$727K 0.05%
+100,000
New +$1.01M
QBTS icon
158
D-Wave Quantum
QBTS
$6.2B
$722K 0.05%
50,000
PUMP icon
159
ProPetro Holding
PUMP
$1.59B
$721K 0.05%
+50,000
New +$598K
RGTI icon
160
Rigetti Computing
RGTI
$4.69B
$702K 0.05%
50,000
WLTH
161
Wealthfront Corp
WLTH
$1.38B
$694K 0.05%
75,000
-75,000
-50% -$686K
LIFE
162
Ethos Technologies Inc
LIFE
$1.17B
$670K 0.04%
+60,000
New +$709K
DYN icon
163
Dyne Therapeutics
DYN
$3.92B
$635K 0.04%
35,000
LRMR icon
164
Larimar Therapeutics
LRMR
$384M
$563K 0.04%
+125,000
New +$500K
ARWR icon
165
Arrowhead Research
ARWR
$10.5B
$470K 0.03%
+7,500
New +$475K
AKTS
166
Aktis Oncology
AKTS
$1.38B
$447K 0.03%
+25,000
New +$485K
TEO icon
167
Telecom Argentina
TEO
$5.65B
$409K 0.03%
+35,000
New +$409K
AAPL icon
168
Apple
AAPL
$4.9T
-87,000
Closed -$23.7M
BBIO icon
169
BridgeBio Pharma
BBIO
$15.9B
-50,000
Closed -$3.82M
BRO icon
170
Brown & Brown
BRO
$23.5B
-187,500
Closed -$14.9M
CCC
171
CCC Intelligent Solutions
CCC
$3.55B
-1,000,000
Closed -$7.95M
CNTA
172
DELISTED
Centessa Pharmaceuticals
CNTA
-50,000
Closed -$1.25M
COHR icon
173
Coherent
COHR
$54.3B
-200,000
Closed -$36.9M
DLO icon
174
dLocal
DLO
$4.26B
-200,000
Closed -$2.83M
EL icon
175
Estee Lauder
EL
$29.7B
-100,000
Closed -$10.5M

Similar funds

Seven Grand Managers's Q1 2026 Portfolio in Review

As of Q1 2026, Seven Grand Managers held 214 positions worth $1.5B, up 14% from $1.31B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Seven Grand Managers deployed $155M of net new capital in Q1 2026, opening 76 new positions and adding to 20 existing holdings. Its largest new stake was L3Harris: 275,000 shares worth $94.9M.

By sector, the portfolio is most concentrated in Industrials at 23% of assets, up from 23% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Sandisk, an estimated $84.7M trimmed.

  • Seven Grand Managers's largest Q1 2026 buy was L3Harris: 275,000 shares worth $94.9M.
  • Seven Grand Managers added most to Medline Inc in Q1 2026, an estimated $59.6M increase.
  • Seven Grand Managers's biggest Q1 2026 reduction was Sandisk, cutting an estimated $84.7M.
  • Seven Grand Managers fully exited T-Mobile US in Q1 2026, selling an estimated $40.6M.
  • Seven Grand Managers's ten largest holdings make up 43% of its $1.5B portfolio in Q1 2026.
  • Seven Grand Managers opened 76 new positions and closed 47 in Q1 2026.
  • Seven Grand Managers's portfolio value rose 14% quarter-over-quarter to $1.5B.

Based on Seven Grand Managers's 13F filing for Q1 2026, filed 6 May 2026.